临床心身疾病杂志
臨床心身疾病雜誌
림상심신질병잡지
JOURNAL OF CLINICAL PSYCHOSOMATIC DISEASES
2014年
z1期
105-105
,共1页
围绝经期功能失调性子宫出血%米非司酮%12.5mg/d%激素水平%子宫内膜厚度
圍絕經期功能失調性子宮齣血%米非司酮%12.5mg/d%激素水平%子宮內膜厚度
위절경기공능실조성자궁출혈%미비사동%12.5mg/d%격소수평%자궁내막후도
Perimenopausal dysfunctional uterine bleeding%Mifepristone%12.5 mg/d%Hormone levels%Endometrial thickness
目的：探讨12.5mg/d米非司酮对围绝经期功能失调性子宫出血患者激素水平与治疗效果的影响。方法：选取我院收治的106例围绝经期功能失调性子宫出血患者为研究对象，采用数字表法分为观察组和对照组各53例，观察组给予米非司酮剂量12.5mg/d口服，对照组给予米非司酮剂量6.25mg/d口服，均连续治疗3个月。比较两组激素水平、子宫内膜厚度、临床疗效。结果：观察组疗效明显高于对照组(96.23% vs 86.78%； P、E2、LH、FSH及子宫内膜厚度均明显低于对照组(6.27±2.19 vs 9.07±3.01，175.90±34.62 vs 203.76±29.46，4.20±1.26 vs 6.75±1.48，4.68±2.27 vs 7.32±2.46，7.08±0.74 vs 8.96±0.88)。结论：12.5mg/d米非司酮治疗有助于改善患者激素水平，提高治疗效果。
目的：探討12.5mg/d米非司酮對圍絕經期功能失調性子宮齣血患者激素水平與治療效果的影響。方法：選取我院收治的106例圍絕經期功能失調性子宮齣血患者為研究對象，採用數字錶法分為觀察組和對照組各53例，觀察組給予米非司酮劑量12.5mg/d口服，對照組給予米非司酮劑量6.25mg/d口服，均連續治療3箇月。比較兩組激素水平、子宮內膜厚度、臨床療效。結果：觀察組療效明顯高于對照組(96.23% vs 86.78%； P、E2、LH、FSH及子宮內膜厚度均明顯低于對照組(6.27±2.19 vs 9.07±3.01，175.90±34.62 vs 203.76±29.46，4.20±1.26 vs 6.75±1.48，4.68±2.27 vs 7.32±2.46，7.08±0.74 vs 8.96±0.88)。結論：12.5mg/d米非司酮治療有助于改善患者激素水平，提高治療效果。
목적：탐토12.5mg/d미비사동대위절경기공능실조성자궁출혈환자격소수평여치료효과적영향。방법：선취아원수치적106례위절경기공능실조성자궁출혈환자위연구대상，채용수자표법분위관찰조화대조조각53례，관찰조급여미비사동제량12.5mg/d구복，대조조급여미비사동제량6.25mg/d구복，균련속치료3개월。비교량조격소수평、자궁내막후도、림상료효。결과：관찰조료효명현고우대조조(96.23% vs 86.78%； P、E2、LH、FSH급자궁내막후도균명현저우대조조(6.27±2.19 vs 9.07±3.01，175.90±34.62 vs 203.76±29.46，4.20±1.26 vs 6.75±1.48，4.68±2.27 vs 7.32±2.46，7.08±0.74 vs 8.96±0.88)。결론：12.5mg/d미비사동치료유조우개선환자격소수평，제고치료효과。
objective:To study effect of hormone levels and treatment effect 12.5 mg/d mifepristone for perimenopausal dysfunctional uterine bleeding. Methods:106 patients with perimenopausal dysfunctional uterine bleeding were divided into observation group and control group, the observation group was given 12.5 mg/d dose mifepristone, control group to 6.25 mg/d dose mifepristone. Hormone level, endometrial thickness, clinical efficacy was compared.Result:observation group curative effect were significantly higher than that control group (96.23% vs 86.78%, P, E2, LH, FSH, endometrial thickness were significantly lower than that control group(6.27±2.19 vs 9.07±3.01,175.90±34.62 vs 203.76±29.46, 4.20±1.26 vs 6.75±1.48,4.68±2.27 vs 7.32±2.46,7.08±0.74 vs 8.96±0.88).Conclusion:12.5 mg/d mifepristone can help improve patients with hormone levels, improve the effect of treatment.
